Macro

Global pharmaceutical sales are projected to exceed $2 trillion by 2032, driven by obesity and inflammatory drugs, according to Evaluate's World Preview 2026 report. Eli Lilly's tirzepatide (Mounjaro/Zepbound) is forecast to generate over $70 billion that year, making it the biggest drug ever, while AbbVie's Skyrizi is expected to be the second top-seller at $33 billion. The report highlights a resurgence in M&A, with Chinese assets accounting for over two-thirds of 2026 deal value. However, challenges include U.S. drug pricing pressures, a patent cliff risking $500 billion in sales, and increasing competition in popular indications.

Artificial intelligence is transforming drug discovery by cutting development timelines from years to weeks, addressing a pipeline where 90% of candidates fail. Peptide-based medicines, built from amino acids, are especially suited for AI-driven optimization, enabling rapid analysis of molecular combinations. Eli Lilly's tirzepatide franchise generated $36.5 billion in 2025 revenue (up 215%), and Novo Nordisk's GLP-1 portfolio reached $34.6 billion. Schrodinger's simulation software, used by 18 of the top 20 pharma companies, posted 12% revenue growth in Q1 2026. AI is also overcoming manufacturing and delivery challenges, positioning peptide drugs as a major biotech growth opportunity.

Eli Lilly and Novo Nordisk are leading the S&P 500 healthcare sector, with a focus on metabolic conditions such as diabetes and obesity. A key development is the emergence of oral obesity therapies, which offer a pill-based alternative to traditional injections, potentially expanding patient access. Both companies' large-scale operations and market capitalizations make them major constituents of the index.

IDEXX Laboratories (IDXX) has underperformed the Nasdaq Composite, with shares down 17.1% year-to-date versus NASX's 11.6% gain, due to softening demand in the companion animal market and FX headwinds. Despite outperforming rival Zoetis (ZTS), the stock trades below key moving averages, reflecting investor caution. Analysts maintain a 'Moderate Buy' consensus, citing a 30.4% upside potential.

President Trump announced via social media a plan to impose 100% tariffs on imported generic drugs starting in August 2028, escalating to 200% after one year, to force manufacturers to move production to the U.S. The proposal targets a nearly $500 billion global industry where generics account for 90% of U.S. prescriptions; India supplies over 50% of these drugs, and China provides most active pharmaceutical ingredients. Industry experts and representatives expressed skepticism, noting generic manufacturers operate on single-digit margins, making the tariffs effectively a "market-exit notice." Building domestic manufacturing takes at least four to five years, according to India's Pharmexcil chairman, suggesting the two-year tariff-free period may be insufficient. The Association for Accessible Medicines called for broader policy changes. Companies with existing U.S. production, like Amphastar and Hikma, are better positioned, while Teva and Viatris face greater exposure. It remains unclear if tariffs apply to finished drugs only or also to those using imported ingredients. New reporting highlights that generic drugmakers, unlike patented pharma giants like Johnson & Johnson and Eli Lilly, operate on thin margins due to price wars—prices can fall 70% in two years after patent expiry—making reshoring less viable. Erez Israeli, CEO of Dr. Reddy's, stated tariffs would force price increases in the U.S., and the Global Trade Research Initiative noted many Indian generics would remain cost-competitive even after 100% tariffs, with costs likely passed to patients, insurers, and providers.

Eli Lilly reported Q1 2026 revenue of $19.80 billion, up 55.5% year-over-year, beating consensus estimates, and raised full-year guidance by $2 billion. The FDA cleared Foundayo, the first any-time-of-day oral GLP-1 drug, which drove 80% new-to-class prescriptions in early launch data. Mounjaro revenue surged 125% to $8.66 billion, and Zepbound rose 80% to $4.16 billion. The company also completed a $6.3 billion Centessa acquisition and a $6.5 billion manufacturing plant investment. However, realized prices fell 13% amid volume gains, and Novo Nordisk filed a false-advertising lawsuit. 24/7 Wall St. set a $1,365.51 price target with a buy rating, citing Foundayo's potential to expand the oral obesity market globally.

Indian stock markets suffered their steepest fall in 10 sessions on Wednesday, extending losses to a third consecutive day. The BSE Sensex dropped 715.06 points (0.92%) to 76,755.05, while the Nifty50 fell 191.45 points (0.79%) to 23,996.25, erasing approximately Rs 4.2-4.25 lakh crore in investor wealth. The selloff was driven by escalating US-Iran tensions—with the 11th consecutive night of US strikes targeting Iranian military infrastructure—and a sharp spike in crude oil prices, with Brent surging 3.5% to $94.20 per barrel and WTI climbing 3.8% to $87.56, raising concerns about supply disruptions through the Strait of Hormuz. Additional pressure came from US President Donald Trump's phased tariff plan on imported generic medicines, proposing zero tariffs for two years starting August 1, 2026, followed by 100% for one year and then 200%, hitting India's dominant pharma export sector. The Indian rupee weakened to 96.36 per dollar, while US Treasury yields rose. Broad-based selling hit banking, IT, auto, and pharma stocks, with foreign institutional investors likely net sellers. Analysts expect near-term volatility to persist, hinging on global crude prices and geopolitical developments.

Eli Lilly shares have surged 13.4% this year and 58% over 52 weeks, while Novo Nordisk has fallen 5% over the same period and 62% since July 2024, driven by diverging fortunes in the GLP-1 drug market. The global obesity drug market reached $66 billion in 2025 and is projected to hit $120 billion by 2030. Lilly now holds a 60% share of prescription obesity revenue, largely due to its Zepbound drug, while the two companies collectively control 87% of the market. Novo Nordisk has introduced Wegovy in pill form this spring, boosting its forecasts, but its shares remain under pressure.

The Trump administration is ending the Medicare Part D Premium Stabilization Demonstration after 2026, eliminating federal subsidies that lowered premiums by 40% in 2025 and 27% in 2026. CMS Administrator Dr. Mehmet Oz defended the decision, calling the $9.8 billion in subsidies a 'bailout' for insurers, and stated that 'every Medicare beneficiary' will retain access to affordable plans. However, a Trump administration official told the Wall Street Journal that only about a quarter of enrollees will see premiums remain flat or lower. Oz claimed premiums will rise by less than $10 for most recipients, but GAO projections indicate that without the program, 30% of enrollees (4 million) would have faced increases of $40–$100 per month, and 7% (1 million) would have seen hikes of at least $100. Starting in 2027, about 30% of enrollees may see monthly increases under $10, while 45% could face hikes of $11–$20. Rising costs for GLP-1 drugs and Inflation Reduction Act changes contributed to premium pressures. Meanwhile, 2.6 million beneficiaries lost Medicare Advantage drug plans after insurers exited markets in 2026.

The Federal Reserve may raise interest rates in October, with CME Group's FedWatch tool showing a 57.7% probability of a hike at the late-October FOMC meeting, following a 44.1% chance in September. Despite the potential for rising rates to hurt many stocks, three are recommended as buys: UnitedHealth Group, which has seen a 20% year-to-date gain and a 54% earnings jump in Q2 2026; JPMorgan Chase, which benefits from higher net interest income, reporting $25.6 billion in Q2; and Chevron, which gains from elevated fuel prices tied to the Iran war and resurging inflation, with shares up over 20% in 2026.

Baron Health Care Fund's Q2 2026 investor letter highlighted Eli Lilly as a top performer in the obesity drug market, which it projects could exceed $150 billion. Eli Lilly's GLP-1 therapies, including the new daily oral Foundayo, gained coverage from all three major pharmacy benefit managers, reversing prior concerns about a price war with Novo Nordisk. Phase 3 data for retatrutide showed weight loss in the high-20% range at higher doses, while eloralintide demonstrated Zepbound-like efficacy. Eli Lilly closed at $1,121.36 per share on August 3, 2026, with a market cap of $1.06 trillion, up 46.40% over 52 weeks.

Eli Lilly plans to file for FDA approval of its next-generation weight-loss drug retatrutide in the first quarter of 2027. In a phase 3 trial, retatrutide achieved average weight loss of up to 28.3% over 80 weeks, surpassing results from Novo Nordisk's Wegovy and even Lilly's own Zepbound. The drug mimics three gut hormones, offering a triple-pathway approach to obesity, and is also being studied for diabetes, sleep apnea, chronic back pain, and liver disease. Lilly's second-quarter revenue rose 48% year over year to $23 billion, driven by its weight-loss portfolio, as the company aims to extend its market lead over Novo Nordisk.

Novo Nordisk shares fell 2.23% after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 and ADR target to $47. Analyst Kerry Holford said the upside from the Wegovy pill that supported the previous Buy rating has already been realized, with consensus and Berenberg modeling around DKK 15 billion in Wegovy pill sales for 2026, leaving little room for surprises. While Berenberg raised its 2026 revenue estimate 2.9% to DKK 296.18 billion and EPS 10.8% to DKK 23.12, it cut 2028 revenue 2.3% to DKK 308.76 billion and EBIT 2.8% to DKK 125.05 billion on weaker CagriSema assumptions. The broker also expects Eli Lilly to capture a disproportionate share of the Medicare weight-loss market, intensifying direct-to-consumer spending in the second half.

Eli Lilly outperformed Novo Nordisk in Q2 GLP-1 drug sales, with Zepbound revenue reaching $4.9 billion (up 46% YoY) versus Wegovy's ~$3 billion (up 1% YoY). Tirzepatide, marketed as Mounjaro and Zepbound, showed superior efficacy in a head-to-head study, achieving 20.2% average weight loss compared to semaglutide's 13.7% over 72 weeks. Eli Lilly also boasts a broader pipeline beyond diabetes and weight loss, including cancer drug Verzenio and Alzheimer's treatment Kisunla, while Novo Nordisk's pipeline is more limited. Despite Novo Nordisk's lower forward P/E of 13.8x versus Eli Lilly's 32.7x, Eli Lilly's faster revenue and earnings growth make it the stronger buy.